-
2023
-
Merck, Eisai decide to discontinue advanced melanoma therapy trial
-
US FDA advisers to weigh full approval for Eisai-Biogen’s Alzheimer’s drug
-
Idorsia Urges DEA to Deschedule Chronic Insomnia Drug Class
-
FDA approves drug which helps to slow progression of rare form of MND
-
Potential Nitrosamine Contamination Results in Another Voluntary Pharmaceutical Recall
-
Sumitomo Pharma’s Ewing Sarcoma Candidate Gains Orphan Drug Status
-
iogen to develop amyloid beta-targeting antibody platform
-
Regenxbio Gene Therapy Candidate Gets Fast Track Status for Duchenne Muscular Dystrophy
-
FDA rejects Eli Lilly’s mirikizumab for ulcerative colitis, citing manufacturing concerns
-
FDA grants breakthrough device status for Genetesis’ CardioFlux MCG